Doublet Shows Activity in Rare, Aggressive Kidney Cancer
There is currently no effective therapy for patients with advanced HLRCC-associated papillary renal cell carcinoma. Treatment with bevacizumab and erlotinib resulted in a confirmed response of 72% in patients with hereditary papillary renal cell carcinoma. The combination was approximately half as effective in patients with sporadic papillary renal cell carcinoma. Bevacizumab (Avastin) combined with erlotinib […]
‘Watch and Wait’ With Small Renal Masses: When and How Should Docs Intervene?
Active surveillance of small renal masses appears to be safe, but if intervention does become necessary, what should trigger it? “We now know that with at least 10 years of data that active surveillance is safe and non-inferior to primary intervention,” said Phillip Pierorazio, MD, of the University of Pennsylvania in Philadelphia, during a presentation […]
Tyrosine Kinase Inhibitor Active in Heavily Treated Renal Cell Carcinoma
NASHVILLE, Tenn. — An investigational multitargeted drug produced objective responses in clear-cell renal cell carcinoma (ccRCC), irrespective of prior exposure to cabozantinib (Cabometyx), a small clinical trial showed. Overall, 12 of 32 patients responded to zanzalintinib, including four of 17 evaluable patients with prior exposure to cabozantinib and eight of 14 without. All but one […]
Fecal Transplants in Kidney Recipients Reduced Resistant Pathogens
In the single-center PREMIX clinical trial, most renal transplant recipients were negative for multidrug-resistant pathogens shortly after receiving fecal microbiota transplants (FMT), with longer times to recurrent infections. Eight of 10 participants who received a least one FMT, and eight of nine participants who received all FMT treatments were multidrug-resistant organism (MDRO) negative by day […]
Medtronic’s Renal Denervation System for Hypertension Splits FDA Panel
A radiofrequency-based renal denervation system for uncontrolled hypertension got a cool reception from FDA advisors who nevertheless left the door open for regulatory approval. On Wednesday, the FDA’s Circulatory System Devices Panel voted 6-7 (with one abstention) that the benefits of the Symplicity Spyral multi-electrode catheter system do not outweigh its risks when used to […]
FDA Panel Backs ReCor’s Renal Denervation System for Hypertension
The Paradise ultrasound renal denervation system got backing from the FDA’s Circulatory System Devices Panel as a possible treatment for hypertension, as manufacturer ReCor continues to hope for regulatory approval. On Tuesday, FDA advisors voted 10-2 that the benefits of the Paradise catheter-based system outweigh its risks when used to reduce blood pressure (BP) in […]
Cystic Renal Masses Often Harbor High-Grade Disease
Almost a fourth of renal cysts had pathologically high-grade disease, which did not have a correlation with growth rate or increase the risk with active surveillance (AS), according to a large retrospective review. Overall, 23% of 387 radiographically confirmed cystic lesions exhibited high-grade pathology. Nonetheless, the potentially more aggressive subset did not affect overall survival, […]
Novel PET Imaging Agent Accurately IDs Clear Cell Renal Cancers
An investigational PET imaging agent — zirconium-89 (89Zr)-deferoxamine (DFO)-girentuximab — identified clear cell renal cell carcinoma (ccRCC) with high sensitivity and specificity, according to results from the phase III ZIRCON trial. Use of the agent achieved sensitivity and specificity rates of 85.5% (95% CI 79.8-89.8) and 87% (95% CI 78.8-92.3), respectively, reported Peter Mulders, MD, […]
Reassuring Findings on Bivalent COVID Booster in Hemodialysis Patients
Anti-spike IgG concentrations against BA.4/5 significantly increased in patients with end-stage renal disease (ESRD) following a bivalent booster, particularly in those without a prior Omicron infection, a case series from Germany found. The study looked at 55 ESRD patients on hemodialysis who had received four prior doses of a monovalent vaccine, including about a third […]
Check Troponin in RCC Patients Before Checkpoint-VEGFR Inhibitor Combo
Advanced renal cell carcinoma (RCC) patients with high serum levels of troponin T had a greater risk of serious cardiac events when treated with an immune checkpoint inhibitor and VEGFR inhibitor combination, data from the phase III JAVELIN Renal 101 trial indicated. For patients assigned to the avelumab (Bavencio) plus axitinib (Inlyta) arm, 17.1% of […]